A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors
NCT 06914128 Brief Summary The study treatment, BAY 3713372, is under development…
Read more arrow_forwardNCT 06914128 Brief Summary The study treatment, BAY 3713372, is under development…
Read more arrow_forwardNCT 06384352 Brief Summary This is a multicenter, open-label, Phase 1 study.…
Read more arrow_forwardNCT 05094336 Brief Summary The primary objective of Parts 1 and 2…
Read more arrow_forwardNCT 06669975 Brief Summary This is a Phase 1/2, multi-regional, multi-center, open-label,…
Read more arrow_forwardNCT 06130553 Brief Summary This is a first time in human (FTiH)…
Read more arrow_forwardNCT 06803680 Brief Summary The goal of this clinical trial is to…
Read more arrow_forwardNCT 05410145 Brief Summary This is a first-in-human (FIH), multicenter, open-label, dose-escalation,…
Read more arrow_forwardNCT 05914116 Brief Summary This is a dose-escalation and dose-expansion Phase 1/2a…
Read more arrow_forwardNCT 06004245 Brief Summary This is a first-in-human, Phase I, open-label, multicenter,…
Read more arrow_forwardNCT 06597721 Brief Summary Adcendo ApS is conducting a phase 1 study…
Read more arrow_forward